These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24446365)

  • 1. Exploiting protein intrinsic flexibility in drug design.
    Lukman S; Verma CS; Fuentes G
    Adv Exp Med Biol; 2014; 805():245-69. PubMed ID: 24446365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics.
    Pantelopulos GA; Mukherjee S; Voelz VA
    Proteins; 2015 Sep; 83(9):1665-76. PubMed ID: 26138282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
    Perola E; Walters WP; Charifson PS
    Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
    Meagher KL; Carlson HA
    J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target flexibility in molecular recognition.
    McCammon JA
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):221-4. PubMed ID: 16181817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistance.
    Barreca ML; Lee KW; Chimirri A; Briggs JM
    Biophys J; 2003 Mar; 84(3):1450-63. PubMed ID: 12609852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
    Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
    J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of receptor structural ensembles for virtual screening using binding site shape analysis and clustering.
    Osguthorpe DJ; Sherman W; Hagler AT
    Chem Biol Drug Des; 2012 Aug; 80(2):182-93. PubMed ID: 22515569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics studies on Mdm2 complexes: an analysis of the inhibitor influence.
    Almerico AM; Tutone M; Pantano L; Lauria A
    Biochem Biophys Res Commun; 2012 Jul; 424(2):341-7. PubMed ID: 22771796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trapping moving targets with small molecules.
    Lee GM; Craik CS
    Science; 2009 Apr; 324(5924):213-5. PubMed ID: 19359579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring experimental sources of multiple protein conformations in structure-based drug design.
    Damm KL; Carlson HA
    J Am Chem Soc; 2007 Jul; 129(26):8225-35. PubMed ID: 17555316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
    Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
    Espinoza-Fonseca LM; Trujillo-Ferrara JG
    Biopolymers; 2006 Nov; 83(4):365-73. PubMed ID: 16817233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K; Mane J; Friesen D; Tuszynski J
    J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2.
    Dastidar SG; Lane DP; Verma CS
    J Am Chem Soc; 2008 Oct; 130(41):13514-5. PubMed ID: 18800837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis.
    Chen J; Wang J; Xu B; Zhu W; Li G
    J Mol Graph Model; 2011 Sep; 30():46-53. PubMed ID: 21764342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein flexibility and ligand recognition: challenges for molecular modeling.
    Spyrakis F; BidonChanal A; Barril X; Luque FJ
    Curr Top Med Chem; 2011; 11(2):192-210. PubMed ID: 20939788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.